

GALL 1205 \$
1614 #9
#1
2/21/98
Attorney Docket No. 205.7
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Choung Kim

Serial No.: 08/735,385

Group No.: 1205

Filed: October 21, 1996

Examiner: K. Weddington

For: PIPERIDINE COMPOUNDS

RECEIVED

Assistant Commissioner for Patents

FEB 20 1998

Washington, D.C. 20231

MAIL ROOM

INFORMATION DISCLOSURE STATEMENT (modified)

List of Sections Forming Part of This Information Disclosure Statement.

The following sections are being submitted for this Information Disclosure Statement:

1. ☒ Preliminary Statements
2. ☒ FORM PTO - 1449 (Modified)
3. ☒ Copies of Listed Information Items Accompanying This Statement

Section 1. Preliminary statements

Applicants submit herewith patents, publications or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 CFR 1.97 (g)), an admission that the information cited is, or is considered to be, material to patentability or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

CERTIFICATE OF MAILING


I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Robin Torres

(Type or print name of person mailing paper)

Date: February 12, 1998

Robin Torres
(Signature of person mailing paper)



Section 3. Copies of Listed Information Items Accompanying This Statement

Legible copies of all items listed in Form PTO-1449 accompany this information statement.

Reg. No. 35,071


Tel. No.: (650) 572-6569


SIGNATURE OF ATTORNEY

Mark L. Bosse
Type or print name of attorney

Gilead Sciences, Inc.
333 Lakeside Drive
P.O. Address

Foster City, CA 94404



Gp 1205 \$

Attorney Docket No. 205.7
PATENT

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Choung Kim

Serial No.: 08/735,385

Group No.: 1205

Filed: October 21, 1996

Examiner: K. Weddington

For: PIPERIDINE COMPOUNDS

Assistant Commissioner for Patents

Washington, D.C. 20231

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT BEFORE
MAILING DATE OF EITHER A FINAL ACTION OR NOTICE
OF ALLOWANCE (37 CFR 1.97 (c))**

**TIME TRANSMITTAL OF ACCOMPANYING INFORMATION
DISCLOSURE STATEMENT**

1. The information disclosure statement transmitted herewith is being filed *after* three months of the filing date of this national application or the date of entry of the national stage as set forth in § 1.491 in an international application or after the mailing date of the first Office action on the merits, whichever event occurred last but *before* the mailing date of either:

- (1) a final action under § 1.113 or
 - (2) a notice of allowance under § 1.311,
- whichever occurs first.

CERTIFICATE OF MAILING (37 CFR 1.8 (a))

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Date:

February 12, 1998

Robin Torres

(Type or print name of person mailing paper)

Robin Torres

(Signature of person mailing paper)

CERTIFICATION OR FEE

2. Accompany this transmittal is

A. ☐ a certification as specified in 37 CFR 1.97 (e)

OR

B. ☒ the fee set forth in 37 CFR 1.17 (p) for submission of an information disclosure statement under § 1.97 (c). (\$240.00).

FEE PAYMENT

3. Applicant elects the option to pay the fee set forth in 37 CFR 1.17 (p) for submission of an information disclosure statement under § 1.97 (c). (\$240.00).

Fee due \$ 240.00

METHOD OF PAYMENT OF FEE

4.

☐ attached is check in the sum of \$ _____


☒ charge Account No. 07-1250 the sum of \$ 240.00

A duplicate of this request is attached.

If any additional fees are due, please charge Account No. 07-1250

Reg. No. 35,071

Tel. No.: (650) 572-6569



SIGNATURE OF ATTORNEY

Mark L. Bosse
Type or print name of attorney

Gilead Sciences, Inc.
333 Lakeside Drive
P.O. Address

Foster City, CA 94404

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(37 CFR 1.98(b))</small>	ATTY DOCKET NO.: 205.7	SERIAL NO.: 08/735,385
	APPLICANT: Kim, Choung	
	FILING DATE: 10/21/96	GROUP ART UNIT:

U.S. PATENT DOCUMENTS

EXAMR'S INITIALS	PATENT NO.	ISSUE DATE	PATENTEE	CLASS/ SUBCLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAMR'S INITIALS	PATENT NO.	PUBLICATION DATE	COUNTRY	CLASS/ SUBCLASS	TRANSLATION YES/NO

OTHER DOCUMENTS

EXAMR'S INITIALS	ARTICLE
	Chahoua et al., "Synthesis of (-)-Shikimate and (-)-Quinate 3-Phosphates by Differentiation of the Hydroxyl Functions of (-)-Shikimic and (-)-Quinic Acids", 57:5798-5801, J ORG CHEM, 1992
	Fernandez et al., "New and Efficient Enantiospecific Synthesis of (-)-Methyl 5-epi-Shikimate and Methyl 5-epi-Quinate from (-)-Quinic Acid", 38(29):5225-5228, TET LETT, 1997
	Kim et al., "Influenza Neuraminidase Inhibitors Possessing a Novel Hydrophobic Interaction in the Enzyme Active Site: Design, Synthesis, and Structural Analysis of Carbocyclic Sialic Acid Analogues with Potent Anti-Influenza Activity", 119:681-690, J AM CHEM SOC, 1997
	Meindl et al., "2-Deoxy-2,3-dehydrosialic acids. 3. Inhibition of Vibrio cholerae[comma]neuraminidase by oxidation products of 2-deoxy-2,3-dehydro-N-acetylneuraminic acid", 73:42027b, CHEM AB, 1970
	Ulibarri et al., "Construction of the Bicyclic Core Structure of the Eneidyne Antibiotic Esperamicin-A1 in Either Anantiomeric Form from (-)-Quinic Acid", 60:2753-2761, J ORG CHEM, 1995

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.